Early HCV viral kinetics under DAAs may optimize duration of therapy in patients with compensated cirrhosis-Reference-Cited by-同舟云学术

Early HCV viral kinetics under DAAs may optimize duration of therapy in patients with compensated cirrhosis

Published:2018-12-28 Issue:5 Volume:39 Page:826-834
ISSN:1478-3223
Container-title:Liver International
language:en
Short-container-title:Liver Int

Author:

Gambato Martina¹²^ORCID,Canini Laetitia³⁴^ORCID,Lens Sabela¹^ORCID,Graw Frederik⁵,Perpiñan Elena¹,Londoño Maria‐Carlota¹,Uprichard Susan L.³,Mariño Zoe¹,Reverter Enric¹^ORCID,Bartres Concepcio¹,González Patricia¹,Pla Anna¹,Costa Josep⁶,Burra Patrizia²^ORCID,Cotler Scott J.³,Forns Xavier¹,Dahari Harel³^ORCID

Affiliation:

1. Liver Unit Hospital Clinic, IDIBAPS, CIBEREHD, University of Barcelona Barcelona Spain

2. Multivisceral Transplant Unit Padua University Hospital Padua Italy

3. The Program for Experimental & Theoretical Modeling, Division of Hepatology Loyola University Medical Center Maywood Illinois

4. Centre for Immunity, Infection and Evolution University of Edinburgh Edinburgh UK

5. Center for Modeling and Simulation in the Biosciences, BioQuant Center Heidelberg University Heidelberg Germany

6. Microbiology Service Hospital Clínic, IDIBAPS, CIBEREHD, University of Barcelona Barcelona Spain

Funder

Instituto de Salud Carlos III

National Institutes of Health

European Association for the Study of the Liver

Publisher

Wiley

Subject

Hepatology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/liv.14014

Reference37 articles.

1. Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study

2. Reduction in liver transplant wait-listing in the era of direct-acting antiviral therapy

3. Ledipasvir-sofosbuvir with or without ribavirin to treat patients with HCV genotype 1 infection and cirrhosis non-responsive to previous protease-inhibitor therapy: a randomised, double-blind, phase 2 trial (SIRIUS)

4. Ledipasvir and sofosbuvir in patients with genotype 1 hepatitis C virus infection and compensated cirrhosis: An integrated safety and efficacy analysis

5. ABT-450/r–Ombitasvir and Dasabuvir with Ribavirin for Hepatitis C with Cirrhosis

Cited by 17 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy of 8-Week Daclatasvir-Sofosbuvir Regimen in Chronic Hepatitis C: A Systematic Review and Meta-Analysis;2024-09-12

2. Early Viral Kinetics in Patients with Chronic Hepatitis C Treated with Direct-Acting Antivirals;Viral Hepatitis Journal;2023-12-26

3. Pre‐existing, treatment‐specific resistance‐associated substitutions in hepatitis C virus genotype 1 and 3 and viral RNA titers during treatment with direct‐acting antivirals;APMIS;2023-06-25

4. Modeling-Based Response-Guided Hepatitis C Treatment During Pregnancy and Postpartum;Open Forum Infectious Diseases;2023-01-20

5. Modeling-Based Response-Guided DAA Therapy for Chronic Hepatitis C to Identify Individuals for Shortening Treatment Duration;Open Forum Infectious Diseases;2022-03-22